top of page



Esketamine (Spravato™) is FDA-approved for treatment-resistant depression.  It is chemically related to ketamine, which is also used for depression.  Given intranasally, esketamine must be administered and monitored in an approved clinic, and will require 2 hours of observation in the clinic following each administration.

The course of treatment is twice a week for 4 weeks, then weekly to every other week indefinitely.

An evaluation in the office is required before approval for ketamine or esketamine treatment, even if you have received ketamine treatments somewhere else in the past.  Treatment is coordinated by Lott Behavioral Health, which is approved for giving esketamine (Spravato™) treatments, as listed in the treatment locator.

We are in Lisle, IL off I-88 with convenient access from Naperville, Wheaton, Winfield, Oakbrook, Downers Grove, Lombard, Hinsdale, and other surrounding areas.  Please call 630-687-1653 to schedule an evaluation.

For more information, also see the official Spravato™ website , our esketamine FAQ page, and our ketamine FAQ page.

bottom of page